Objective:To explore the effects of three classic traditional Chinese medicine (TCM) formulae,Dahuang Huanglian Xiexin Decoction (DHXD),Fuzi Lizhong pills (FLP) and Liushen pills (LSP),in suppressing gastric cancer gr...Objective:To explore the effects of three classic traditional Chinese medicine (TCM) formulae,Dahuang Huanglian Xiexin Decoction (DHXD),Fuzi Lizhong pills (FLP) and Liushen pills (LSP),in suppressing gastric cancer growth in mice and provide evidence for their clinical applications.Methods:MGC-803 cells (5 × 106 per mouse) were injected into the subcutaneous tissues of the neck and back of nude mice.One week later,the mice were divided into three batches (9 total groups) based on tumor size and a random number table.Within each batch,the mice were subdivided into control,low-and high-dose groups for the three classic formulae.After 21-d treatment,the mice were observed for their general conditions,and then sacrificed.Tumor tissues were harvested and weighed,and the tumor inhibition rate was calculated.Results:Compared with the control group,body weight in the low-and high-dose DHXD and FLP groups showed no significant change (P >.05),while the high-dose LSP group had significantly lower body weight (P =.049).Compared with the control group,the low-and high-dose DHXD groups showed no significant inhibitory effect on xenograft tumor growth (P >.05);lowdose FLP showed an inhibitory effect on tumor growth (P =.039),while high-dose LSP had a more significant effect (P =.004).Conclusions:DHXD did not inhibit xenograft tumor growth in mice.In contrast,low-dose FLP had a measurable inhibitory effect,and high-dose LSP more significantly suppressed xenograft tumor growth in mice.展开更多
Background:From early experience,some Traditional Chinese Medicine and Arbidol had effects of against COVID-19,infer that the combination of Liushen capsules and Arbidol may further increase the therapeutic.Methods/De...Background:From early experience,some Traditional Chinese Medicine and Arbidol had effects of against COVID-19,infer that the combination of Liushen capsules and Arbidol may further increase the therapeutic.Methods/Design:We conducted a randomized,blank parallel-controlled,open-label,multi-center,basal therapy-loaded design clinical trial.A total of 40 patients are going to be recruited after satisfying the criteria.Participants will be allocated randomly into the treatment group with the combination of Arbidol and Liushen capsules and the control group with the basic therapy.Each group will receive treatment at least 7-days or until the virus becomes negative,and visits after drug administration at day 3(visit 1),the day when the virus becomes negative(visit 2),day 7(visit 3),the day before discharge(visit 4)and day 28(visit 5),to collect their survival status and disease prognosis so that the efficacy and safety of a combination of Arbidol and Liushen capsule will be evaluated.Discussion:We described the protocol of the first clinical trial for treatment COVID-19 by using a combination of Arbidol and Liushen capsules.The results of this study will provide a basis for the design and sample size estimate of subsequent large-scale clinical trials.Trial registration:This study has been registered at Chinese clinical trial Registry(chictr.org.cn):ChiCTR2000029993.展开更多
基金This study is funded by National Natural Science Foundation of China(81373879).
文摘Objective:To explore the effects of three classic traditional Chinese medicine (TCM) formulae,Dahuang Huanglian Xiexin Decoction (DHXD),Fuzi Lizhong pills (FLP) and Liushen pills (LSP),in suppressing gastric cancer growth in mice and provide evidence for their clinical applications.Methods:MGC-803 cells (5 × 106 per mouse) were injected into the subcutaneous tissues of the neck and back of nude mice.One week later,the mice were divided into three batches (9 total groups) based on tumor size and a random number table.Within each batch,the mice were subdivided into control,low-and high-dose groups for the three classic formulae.After 21-d treatment,the mice were observed for their general conditions,and then sacrificed.Tumor tissues were harvested and weighed,and the tumor inhibition rate was calculated.Results:Compared with the control group,body weight in the low-and high-dose DHXD and FLP groups showed no significant change (P >.05),while the high-dose LSP group had significantly lower body weight (P =.049).Compared with the control group,the low-and high-dose DHXD groups showed no significant inhibitory effect on xenograft tumor growth (P >.05);lowdose FLP showed an inhibitory effect on tumor growth (P =.039),while high-dose LSP had a more significant effect (P =.004).Conclusions:DHXD did not inhibit xenograft tumor growth in mice.In contrast,low-dose FLP had a measurable inhibitory effect,and high-dose LSP more significantly suppressed xenograft tumor growth in mice.
基金This work was supported by the Science research project of the Guangdong Province[Grant No.2020B111110001]Guangzhou Medical University High-level University Clinical Research and Cultivation Program(Guangzhou Medical University released[2017]No.159,160).
文摘Background:From early experience,some Traditional Chinese Medicine and Arbidol had effects of against COVID-19,infer that the combination of Liushen capsules and Arbidol may further increase the therapeutic.Methods/Design:We conducted a randomized,blank parallel-controlled,open-label,multi-center,basal therapy-loaded design clinical trial.A total of 40 patients are going to be recruited after satisfying the criteria.Participants will be allocated randomly into the treatment group with the combination of Arbidol and Liushen capsules and the control group with the basic therapy.Each group will receive treatment at least 7-days or until the virus becomes negative,and visits after drug administration at day 3(visit 1),the day when the virus becomes negative(visit 2),day 7(visit 3),the day before discharge(visit 4)and day 28(visit 5),to collect their survival status and disease prognosis so that the efficacy and safety of a combination of Arbidol and Liushen capsule will be evaluated.Discussion:We described the protocol of the first clinical trial for treatment COVID-19 by using a combination of Arbidol and Liushen capsules.The results of this study will provide a basis for the design and sample size estimate of subsequent large-scale clinical trials.Trial registration:This study has been registered at Chinese clinical trial Registry(chictr.org.cn):ChiCTR2000029993.
